Tag: biotech

This week on JobMakers, Host Denzil Mohammed talks with Dr. Bernat Olle, co-founder and CEO of Vedanta Biosciences, about his journey from Catalonia, Spain, to Cambridge, Massachusetts, where he continued his Chemical Engineering studies at MIT. Navigating the complex immigration system while seeking purpose in his career, he eventually found his calling and was lucky enough to remain in the U.S. to see it through: designing a new class of medicines to modulate the human microbiome. They duscuss how everyone wins when foreign-born talent is welcomed into vibrant, entrepreneurial ecosystems like those in the U.S., when they’re able to collaborate with others from the U.S. and around the world and come up with incredible ideas to benefit all people. Bernat also expresses a sense of kinship with immigrants far removed from the labs and boardrooms. He knows that the same aspiration – opportunity – attracted those who came here with nothing but a suitcase and a dream, as you’ll discover in this week’s JobMakers.

Guest:
Dr. Bernat Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. He has been a member of the founding teams of several companies of the PureTech portfolio and served as a member of the Board of Directors of Vedanta Biosciences and Follica Biosciences. In 2013 Dr. Olle was named “Innovator of the Year” in MIT Technology Review Spain’s “Innovators under 35” awards. He also received the 2019 Barry M. Portnoy Immigrant Entrepreneur Award from The Immigrant Learning Center. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. During his graduate work, Dr. Olle was awarded the “la Caixa” fellowship. Dr. Olle received his B.S. in Chemical Engineering from Universitat Rovira i Virgili, in Catalonia, his M.S. and PhD. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.

Member Post

 

Listen here: https://www.angelinvestboston.com/tim-spong-vistapath-bio A terrible error in a lab led Tim Spong to start a company to improve the reliability and efficiency of pathology labs; big industry players are noticing. This interview was part of my due diligence on Tim’s startup, VistaPath Bio. Subsequently, I invested in the company. Preview Open

Join Ricochet!

This is a members-only post on Ricochet's Member Feed. Want to read it? Join Ricochet’s community of conservatives and be part of the conversation. Join Ricochet for Free.

Eli Dourado, a senior research fellow at Utah State University, joins Brian Anderson to debunk myths about the great stagnation, discuss new technologies that are on the precipice of unleashing growth, and detail the regulatory strictures and complacency that stand in their way.

Find the transcript of this conversation and more at City Journal.

Elizabeth Holmes and the Power of Imagination

 

Theranos founder, chairwoman, and C.E.O. Elizabeth Holmes, in Palo Alto, California, September 2014.A 19-year-old college student had a revolutionary idea that she imagined would make her rich and famous. She quit college and founded a start-up, attracting incredible attention, investors like Lawrence Ellison of Oracle, and a board of directors that included Henry Kissinger and George Schultz. She dressed just like Steve Jobs, in black turtlenecks. She had huge, mesmerizing blue eyes and a very deep voice for a woman. She was sought after for interviews, TED talks, and hailed as a pioneer in medical advances. She claimed that the cost savings using her technology would be in the billions.

Her technology concept was cheap, reliable blood testing done with only a fingerprick, using a device that could test for up to 240 different things. She claimed that she was driven by integrity and the desire to help others.

. . . [T]here’s a tremendous responsibility. I think about it all the time in the context of my mom. And the information that we’re generating, she does all of her tests through us, knowing that we’re right, every single time, and knowing that we’re not compromising on quality, and knowing that we’re, in every action that we take, approaching this with a seriousness that it deserves, in the context of what it means to say to someone, “You don’t have breast cancer” or “You do have breast cancer,” has driven our culture in a huge way.

Throwing Out the Baby with the Culture Medium

 

Over in the Member Feed, Pseudodionysius started an *ahem* spirited conversation regarding eugenics and the dangers of biotechnology. If you’re interested in the subject — and you should be — get yourself caught-up and add your own thoughts (you’ll need to be a member, though; that’s how things work here).

I’m generally a techno-optimist: Despite all the death, horror, and evil technology has enabled, it’s one of the primary means by which we empower our better angels. The same knowledge that gives us bioweapons gives us vaccines; the same understanding that lets us build weapons of unimaginable destructiveness lets us harness energy at the atomic level; the same Internet that makes it easier to distribute child pornography helps us provide micro-loans. The Tree of Knowledge almost always contains the potential for both good and evil.

Member Post

 

The Twitterverse, the media, and Hillary Clinton are up in arms about a new pharmaceutical start-up that bought the rights to Daraprim, a drug that helps offset the ravages of AIDS. Turing's CEO explains why the company raised the price of Daraprim from $13.50 to $750 a pill http://t.co/eJrIk01Lej pic.twitter.com/wGBLATpzlv — Bloomberg TV (@BloombergTV) September […]

Join Ricochet!

This is a members-only post on Ricochet's Member Feed. Want to read it? Join Ricochet’s community of conservatives and be part of the conversation. Join Ricochet for Free.

Member Post

 

I’m finally sorta breaking the fourth wall of Ricochet. Tomorrow (Jan 30) at 1PM EST I’ll be hosting a live Google Hangout with Dr. Rob Carlson for one of my clients, the Public Library of Science (more commonly known as PLOS). I manage their Synthetic Biology Community page and do some small-scale writing for them. […]

Join Ricochet!

This is a members-only post on Ricochet's Member Feed. Want to read it? Join Ricochet’s community of conservatives and be part of the conversation. Join Ricochet for Free.